Article Text

PDF
Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance
  1. Taro Kishi
  1. Fujita Health University School of Medicine, Toyoake, Japan; tarok@fujita-hu.ac.jp

Statistics from Altmetric.com

ABSTRACT FROM: Zheng W, Xiang YT, Xiang YQ, et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatr Scand 2016;134:385–98.

What is already known on this topic

Although a previous meta-analysis showed that topiramate-antipsychotic cotreatment improved the psychopathology and prevented/reduced weight gain in patients with schizophrenia,1 the number of patients and studies included in the analysis were small (8 randomised controlled trials (RCTs), 439 patients). Therefore, Zheng et al conducted a systematic review and meta-analysis to achieve more robust evidence with respect to the efficacy for psychopathology and body weight of topiramate adjunctive therapy in antipsychotic-treated schizophrenia (16 RCTs, 934 patients).

Methods of the study

This study included RCTs of antipsychotic cotreatment with topiramate in patients with schizophrenia-spectrum disorders (schizophrenia, schizophreniform disorder, schizoaffective disorder). PubMed, PsycINFO, Embase, Cochrane Library databases, the Cochrane Controlled Trials Register and Chinese databases (WanFang Database, Chinese Biomedical database and China Journal Net) were searched until June 2015, without language restriction. Moreover, reference …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.